La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ImmunoGen Gestion

Gestion contrôle des critères 2/4

Le PDG ImmunoGen's est Mark Enyedy, nommé en May2016, a un mandat de 6.5 ans. La rémunération annuelle totale est $ 7.44M, composée du salaire de 9.9% et des bonus 90.1%, y compris les actions et options de la société. détient directement 0.2% des actions de la société, d'une valeur de € 2.10M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.4 ans et 10.8 ans.

Informations clés

Mark Enyedy

Directeur général

US$7.4m

Rémunération totale

Pourcentage du salaire du PDG	9.9%
Durée du mandat du directeur général	6.5yrs
Propriété du PDG	0.2%
Durée moyenne d'occupation des postes de direction	2.4yrs
Durée moyenne du mandat des membres du conseil d'administration	10.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Mark Enyedy a-t-elle évolué par rapport aux bénéfices de ImmunoGen?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2022	n/a	n/a	-US$201m
Jun 30 2022	n/a	n/a	-US$161m
Mar 31 2022	n/a	n/a	-US$129m
Dec 31 2021	US$7m	US$735k	-US$139m
Sep 30 2021	n/a	n/a	-US$71m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$5m	US$714k	-US$44m
Sep 30 2020	n/a	n/a	-US$71m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$89m
Dec 31 2019	US$4m	US$710k	-US$104m
Sep 30 2019	n/a	n/a	-US$151m
Jun 30 2019	n/a	n/a	-US$176m
Mar 31 2019	n/a	n/a	-US$174m
Dec 31 2018	US$9m	US$687k	-US$169m
Sep 30 2018	n/a	n/a	-US$140m
Jun 30 2018	n/a	n/a	-US$150m
Mar 31 2018	n/a	n/a	-US$117m
Dec 31 2017	US$3m	US$670k	-US$96m
Sep 30 2017	n/a	n/a	-US$117m
Jun 30 2017	n/a	n/a	-US$105m
Mar 31 2017	n/a	n/a	-US$142m
Dec 31 2016	US$569k	US$325k	-US$157m

Rémunération vs marché: La rémunération totale de Mark ($USD 7.44M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.43M ).

Rémunération et revenus: La rémunération de Mark a augmenté alors que l'entreprise n'est pas rentable.

PDG

Mark Enyedy (58 yo)

6.5yrs

Titularisation

US$7,440,507

Compensation

Mr. Mark Joseph Enyedy is Non-Executive Director at Ergomed plc since June 10, 2021. He has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and served as its Interim Pr...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Mark Enyedy	President	6.5yrs	US$7.44m	0.20% € 2.1m
Susan Altschuller	Senior VP & CFO	2.3yrs	US$1.53m	0% € 0
Anna Berkenblit	Senior VP & Chief Medical Officer	7.6yrs	US$2.51m	0.050% € 531.7k
Stacy Coen	Senior VP & Chief Business Officer	2.4yrs	US$1.61m	0.0032% € 34.6k
Renee Lentini	VP of Finance & Principal Accounting Officer	1.8yrs	pas de données	0.0083% € 88.3k
Courtney O'Konek	Senior Director of Corporate Communications & Investor Relations	no data	pas de données	pas de données
Joseph Kenny	VP, Acting General Counsel	no data	pas de données	pas de données
Audrey Bergan	Senior VP & Chief HR Officer	4.3yrs	pas de données	pas de données
Theresa Wingrove	Senior Vice President of Regulatory Affairs & Quality	no data	US$1.27m	0.037% € 396.5k
Mary Huizinga	Senior VP & Head of Medical Affairs	less than a year	pas de données	pas de données

2.4yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe de direction de IMU est considérée comme expérimentée (ancienneté moyenne 2.4 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Mark Enyedy	President	6.5yrs	US$7.44m	0.20% € 2.1m
Stephen McCluski	Independent Chairman	15.6yrs	US$406.07k	0% € 0
Dean Mitchell	Independent Director	10.8yrs	US$365.07k	0.042% € 448.5k
Kristine Peterson	Independent Director	10.8yrs	US$375.07k	0% € 0
Helen Thackray	Independent Director	1.2yrs	US$374.79k	0% € 0
Richard Wallace	Independent Director	15yrs	US$368.07k	0% € 0
Stuart Arbuckle	Independent Director	4.8yrs	US$358.07k	0% € 0
Mark A. Goldberg	Independent Director	11yrs	US$365.07k	0.024% € 259.4k
Tracey McCain	Independent Director	less than a year	US$351.30k	0% € 0

10.8yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration IMU sont chevronnés et expérimentés (durée moyenne d'administration 10.8 ans).

ImmunoGen Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

ImmunoGen, Inc. Announces Mature Data from Forward II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer, Regardless of Platinum Status

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.17 loss in 1Q 2020)

ImmunoGen, Inc. Provides Revenue Guidance for the Year of 2021

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

Executive Officer has left the company

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

New 90-day high: €6.39

ImmunoGen, Inc. Enters into Collaboration and Option Agreement with Subsidiary of Jazz Pharmaceuticals plc

New 90-day high: €5.29

ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

Third quarter 2020 earnings released: US$0.13 loss per share

Revenue beats expectations

New 90-day high: €4.98

ImmunoGen, Inc. Announces Executive Changes, Effective on January 1, 2021

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Announces Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

New 90-day high: €4.63

ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

New 90-day low - €2.99

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi